Weight gain at 3 months of antiretroviral therapy is strongly associated with survival: Evidence from two developing countries

AIDS

Volumn 23, Issue 7, 2009, Pages 853-861

  Madec, Yoann ^a   Szumilin, Elisabeth ^b   Genevier, Christine ^b   Ferradini, Laurent ^b,c   Balkan, Suna ^b   Pujades, Mar ^d   Fontanet, Arnaud ^a  

^a INSTITUT PASTEUR   (France)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c Khmero Sovietic Friendship Hospital   (Cambodia)

^d EPICENTRE   (France)

Author keywords

Developing countries; HIV; Monitoring tool; Mortality; Weight

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; FEMALE; GEOGRAPHIC DISTRIBUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; POISSON DISTRIBUTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TREATMENT DURATION; WEIGHT GAIN; CAMBODIA; CD4 LYMPHOCYTE COUNT; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; IMMUNOLOGY; KENYA; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAMBODIA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOCOMPROMISED HOST; KENYA; MALE; RNA, VIRAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 67649670097     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832913ee     Document Type: Article

References (31)

1. UNAIDS. 2007: AIDS epidemic updates. http://www.unaids.org/en/ KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2007/default.asp.
2. World Health Organisation. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach; 2003 revision. Available at http://www. who.int/3by5/publications/documents/arv- guidelines/en/index. html.
3. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006;367:1335-1342.
4. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006;296:782- 793.
5. Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, Pinoges L, et al. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 2007;21:2293-2301.
6. Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006;42:252-259.
7. Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS 2007;21:351-359.
8. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005;41:217-224.
9. Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005;353:2325-2334.
10. Harries AD, Schouten EJ, Libamba E. Scaling up antiretroviral treatment in resource-poor settings. Lancet 2006; 367:18701872.
11. Van Damme W, Kober K, Laga M. The real challenges for scaling up ART in sub-Saharan Africa. AIDS 2006;20:653-656.
12. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510.
13. Bagchi S, Kempf MC, Westfall AO, Maherya A, Willig J, Saag MS. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin Infect Dis 2007; 44:135-138.
14. Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007;44:128-134.
15. Erikstrup C, Kallestrup P, Zinyama R, Gomo E, Mudenge B, Gerstoft J, Ullium H. Predictors of mortality in a cohort of HIV-1-infected adults in rural Africa. J Acquir Immune Defic Syndr 2007;44:478-483.
16. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antire- troviral therapy. PLoS Med 2008;5:e109.
17. Malvy E, Thiebaut R, Marimoutou C, Dabis F. Weight loss and body mass index as predictors of HIV disease progression to AIDS in adults. Aquitaine cohort, France, 1985-1997. J Am Coll Nutr 2001;20:609-615.
18. Paton NI, Sangeetha S, Earnest A, Bellamy R. The impact of malnutrition on survival and the CD4 count response in HIV-infected patients starting antiretroviral therapy. HIV Med 2006; 7:323-330.
19. World Health Organisation. Working Document on Monitoring and Evaluating of National ART Programmes in the Rapid Scale-up to 3 by 5. http:/r/www.who.int/ 3by5/publications/documents/ artindicators/en/index.html.
20. Silva M, Skolnik PR, Gorbach SL, Spiegelman D, Wilson IB, Fernandez-DiFranco MG, Knox TA. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998;12:1645-1651.
21. Shikuma CM, Zackin R, Sattler F, Mildvan D, Nyangweso P, Alston B, et al. Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis 2004; 39:1223-1230.
22. Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, Gorbach SL. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;31:230-236.
23. Jerene D, Endale A, Hailu Y, Lindtjorn B. Predictors of early death in a cohort of Ethiopian patients treated with HAART. BMC Infect Dis 2006;6:136.
24. Saghayam S, Kumarasamy N, Cecelia AJ, Solomon S, Mayer K, Wanke C. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India. Clin Infect Dis 2007; 44:295-300.
25. World Health Organisation. Global database on body mass index. Available at http://www.who.int/bmi/index.jsp?introPage=intro-3.htm.
26. Shetty PS, James WP. Body mass index. A measure of chronic energy deficiency in adults. FAO Food Nutr Pap 1994; 56:1-57.
27. Diggle P, Liang K, Zeger S. Fitting smooth curves to longitudinal data. In: Atkinson ACCJC, Pierce DA, Schervish MJ, Titterington DM, editors. Analysing longitudinal data. Oxford: Oxford University Press;1994. pp. 41-47.
28. Bonnet MM, Pinoges LL, Varaine FF, Oberhauser BB, O'Brien DD, Kebede YY, et al. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS 2006;20:1275-1279.
29. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006; 20:1181-1189.
30. Bonard D, Messou E, Seyler C, Vincent V, Gabillard D, Anglaret X. High incidence of atypical mycobacteriosis in African HIV-infected adults with low CD4 cell counts: a 6-year cohort study in Cote d'Ivoire. AIDS 2004; 18:1961-1964.
31. San Lio MM, Carbini R, Germano P, Guidotti G, Mancinelli S, Magid NA, et al. Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique. Clin Infect Dis 2008; 46:1609-1616.